BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

819 related articles for article (PubMed ID: 25666611)

  • 21. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
    Minkkilä A; Saario S; Nevalainen T
    Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression.
    Carrier EJ; Auchampach JA; Hillard CJ
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7895-900. PubMed ID: 16672367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cannabidiol and tetrahydrocannabinol concentrations in commercially available CBD E-liquids in Switzerland.
    Grafinger KE; Krönert S; Broillet A; Weinmann W
    Forensic Sci Int; 2020 May; 310():110261. PubMed ID: 32229319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effect of Orally Administered Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Obesity Parameters in Mice.
    Eitan A; Gover O; Sulimani L; Meiri D; Schwartz B
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights into endocannabinoid degradation and its therapeutic potential.
    Bari M; Battista N; Fezza F; Gasperi V; Maccarrone M
    Mini Rev Med Chem; 2006 Mar; 6(3):257-68. PubMed ID: 16515464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
    Hudson R; Renard J; Norris C; Rushlow WJ; Laviolette SR
    J Neurosci; 2019 Oct; 39(44):8762-8777. PubMed ID: 31570536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.
    Arnold WR; Weigle AT; Das A
    J Inorg Biochem; 2018 Jul; 184():88-99. PubMed ID: 29689453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol.
    Ross HR; Napier I; Connor M
    J Biol Chem; 2008 Jun; 283(23):16124-34. PubMed ID: 18390906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro metabolic formation of a new metabolite, 6 beta-hydroxymethyl-delta 9-tetrahydrocannabinol from cannabidiol through an epoxide intermediate and its pharmacological effects on mice.
    Nagai K; Watanabe K; Narimatsu S; Gohda H; Matsunaga T; Yamamoto I; Yoshimura H
    Biol Pharm Bull; 1993 Oct; 16(10):1008-13. PubMed ID: 8287029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain.
    Alozie SO; Martin BR; Harris LS; Dewey WL
    Pharmacol Biochem Behav; 1980 Feb; 12(2):217-21. PubMed ID: 6246544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constituents of Cannabis Sativa.
    Rock EM; Parker LA
    Adv Exp Med Biol; 2021; 1264():1-13. PubMed ID: 33332000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
    Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
    Dos Santos RG; Hallak JEC; Crippa JAS
    Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system.
    Fezza F; De Simone C; Amadio D; Maccarrone M
    Subcell Biochem; 2008; 49():101-32. PubMed ID: 18751909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Origin of Δ
    Citti C; Russo F; Linciano P; Strallhofer SS; Tolomeo F; Forni F; Vandelli MA; Gigli G; Cannazza G
    Cannabis Cannabinoid Res; 2021; 6(1):28-39. PubMed ID: 33614950
    [No Abstract]   [Full Text] [Related]  

  • 36. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
    Arnold JC; Boucher AA; Karl T
    Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabidiol and positive effects on object recognition memory in an in vivo model of Fragile X Syndrome: Obligatory role of hippocampal GPR55 receptors.
    Manduca A; Buzzelli V; Rava A; Feo A; Carbone E; Schiavi S; Peruzzi B; D'Oria V; Pezzullo M; Pasquadibisceglie A; Polticelli F; Micale V; Kuchar M; Trezza V
    Pharmacol Res; 2024 May; 203():107176. PubMed ID: 38583687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.
    Vann RE; Gamage TF; Warner JA; Marshall EM; Taylor NL; Martin BR; Wiley JL
    Drug Alcohol Depend; 2008 Apr; 94(1-3):191-8. PubMed ID: 18206320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute effects of Δ
    Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
    Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions of cannabinoids with bovine serum albumin.
    Haque SJ; Poddar MK
    Biosci Rep; 1984 Mar; 4(3):239-43. PubMed ID: 6326885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.